IP Library › Granted Patent US 10,053,508
Granted Patent B2
US 10,053,508 · App. 15/599,396 · Granted Aug 21, 2018

Anti P2X7 receptor antibodies and fragments thereof

Inventors: Julian Alexander Barden (North Ryde, AU); Neil Brewis (Stevenage, GB); Philip Jones (Cambridge, GB); Steven Grant (Cambridge, GB)
Assignee: BIOSCEPTRE (AUST) PTY LTD
C07K16/28C07K2317/34C07K2317/565C07K2317/567C07K2317/569C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,053,508
App. No.
15/599,396
Granted
Aug 21, 2018
Kind
B2
Abstract

The invention relates to an antigen binding site for binding to a P2X 7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

Claims (152)

1. An antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula:

FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4

wherein:

FR1, FR2, FR3 and FR4 are each framework regions;

CDR1, CDR2 and CDR3 are each complementarity determining regions;

wherein:

CDR1 has a sequence:

SEQ ID NO: 88

RNHDMG;

CDR2 has a sequence:

SEQ ID NO: 89

AISGSGGSTYYADSVKG;

CDR3 has a sequence:

SEQ ID NO: 9

EPKPMDTEFDY.

2. An antigen binding site for binding to a P2X7 receptor according to claim 1 , wherein

FR4 has a sequence:

SEQ ID NO: 153

WGQGTLVTVSS,

SEQ ID NO: 154

WGQGTLVTVLS,

SEQ ID NO: 155

RSPGTLVTVSS,

SEQ ID NO: 156

PSPGTQVTVSS,

SEQ ID NO: 157

PSPGTLVTVSS,

SEQ ID NO: 158

RSQGTLVTVSS,

SEQ ID NO: 159

WSQGTLVTVSS,

SEQ ID NO: 160

RGQGTLVTVSS,

SEQ ID NO: 161

RFQGTLVTVSS,

SEQ ID NO: 162

WSPGTLVTVSS,

SEQ ID NO: 163

GSPGTLVTVSS,

SEQ ID NO: 164

WGPGTLVTVSS,

SEQ ID NO: 165

RGPGTLVTVSS,

SEQ ID NO: 166

CGPGTLVTVSS,

or

SEQ ID NO: 167

RSCGTLVTVSS.

3. A nucleic acid encoding an antigen binding site according to claim 1 .

4. A method for the treatment of cancer that expresses non-functional P2X7 receptor in an individual including the step of administering an antigen binding site according to claim 1 to an individual requiring treatment for said cancer.

5. An antigen binding site for binding to a P2X7 receptor according to claim 2 , wherein

FR1 has a sequence:

SEQ ID NO: 139

EVQLLESGGGLVQPGGSLRLSCAASGFTF.

6. An antigen binding site for binding to a P2X7 receptor according to claim 5 , wherein

FR2 has a sequence:

SEQ ID NO: 145

WVRQAPGKGLEWVS.

7. An antigen binding site for binding to a P2X7 receptor according to claim 6 , wherein

FR3 has a sequence:

SEQ ID NO: 148

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCA.

8. A nucleic acid of claim 3 , wherein

FR4 has a sequence:

SEQ ID NO: 153

WGQGTLVTVSS,

SEQ ID NO: 154

WGQGTLVTVLS,

SEQ ID NO: 155

RSPGTLVTVSS,

SEQ ID NO: 156

PSPGTQVTVSS,

SEQ ID NO: 157

PSPGTLVTVSS,

SEQ ID NO: 158

RSQGTLVTVSS,

SEQ ID NO: 159

WSQGTLVTVSS,

SEQ ID NO: 160

RGQGTLVTVSS,

SEQ ID NO: 161

RFQGTLVTVSS,

SEQ ID NO: 162

WSPGTLVTVSS,

SEQ ID NO: 163

GSPGTLVTVSS,

SEQ ID NO: 164

WGPGTLVTVSS,

SEQ ID NO: 165

RGPGTLVTVSS,

SEQ ID NO: 166

CGPGTLVTVSS,

or

SEQ ID NO: 167

RSCGTLVTVSS.

9. A nucleic acid of claim 8 , wherein

FR1 has a sequence:

SEQ ID NO: 139

EVQLLESGGGLVQPGGSLRLSCAASGFTF.

10. A nucleic acid of claim 9 , wherein

FR2 has a sequence:

SEQ ID NO: 145

WVRQAPGKGLEWVS.

11. A nucleic acid of claim 10 , wherein

FR3 has a sequence:

SEQ ID NO: 148

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCA.

12. A method of claim 4 , wherein

FR4 has a sequence:

SEQ ID NO: 153

WGQGTLVTVSS,

SEQ ID NO: 154

WGQGTLVTVLS,

SEQ ID NO: 155

RSPGTLVTVSS,

SEQ ID NO: 156

PSPGTQVTVSS,

SEQ ID NO: 157

PSPGTLVTVSS,

SEQ ID NO: 158

RSQGTLVTVSS,

SEQ ID NO: 159

WSQGTLVTVSS,

SEQ ID NO: 160

RGQGTLVTVSS,

SEQ ID NO: 161

RFQGTLVTVSS,

SEQ ID NO: 162

WSPGTLVTVSS,

SEQ ID NO: 163

GSPGTLVTVSS,

SEQ ID NO: 164

WGPGTLVTVSS,

SEQ ID NO: 165

RGPGTLVTVSS,

SEQ ID NO: 166

CGPGTLVTVSS,

or

SEQ ID NO: 167

RSCGTLVTVSS.

13. The method of claim 12 , wherein

FR1 has a sequence:

SEQ ID NO: 139

EVQLLESGGGLVQPGGSLRLSCAASGYTF.

14. The method of claim 13 , wherein

FR2 has a sequence:

SEQ ID NO: 145

WVRQAPGKGLEWVS.

15. The method of claim 14 , wherein

FR3 has a sequence:

SEQ ID NO: 148

RFTISRDNSKNTLYLQMNSLRAEDTAVYYCA.

Priority Claims (1)
AU 2009903928 · Aug 20, 2009 · national
Continuity (3)
Continuation 14671254 · Mar 27, 2015
Continuation 13391619
Related Publication 20170327576A1 · Nov 16, 2017